The global inflammatory bowel disease treatment market size was estimated to be USD 26.65 billion in 2023 and is expected to reach at USD 49.76 billion by 2034 with a CAGR of 5.84% during the forecast period 2024-2034. Rising prevalence of ulcerative colitis & Crohn's disease, growing demand for the early diagnosis of the disease, surge in adequate reimbursement, increasing number of patients undergoing treatment for IBD, rising awareness regarding the benefits of drugs such as corticosteroids, biologics, & others, growing technological developments such as the use of single-cell RNA sequencing, surge in research & development activities, increasing interest in the use of biologics for the treatment of these conditions, rising launch of innovative products by the key players, and growing approvals of the novel drugs for the treatment of inflammatory bowel disease by regulatory bodies are the key factors propelling the market growth.
Growing approvals of the novel drugs for the treatment of inflammatory bowel disease by regulatory bodies is predicted to boost the market growth during the forecast period. Inflammatory bowel disease (IBD) encompasses two conditions, namely Ulcerative colitis and Crohn's disease, characterized by prolonged inflammation of the gastrointestinal (GI) tract. Persistent inflammation can lead to damage in the GI tract. Treatment for irritable bowel disease is focused on mitigating the inflammation responsible for the associated signs and symptoms. Ideally, this approach aims not only to alleviate symptoms but also to achieve long-term remission and reduce the risks of complications. For instance, in May 2023, According to a statement from AbbVie, the FDA has approved RINVOQ (upadacitinib) for the treatment of people with moderately to severely active Crohn's disease.
By drug class, TNF inhibitors was the highest revenue-grossing segment in the global inflammatory bowel disease treatment market in 2023 owing to the growing focus on development of TNF inhibitors by the key market players and surge in number of clinical trial procedures. For instance, in October 2023, Phase 3 clinical trials are presently being conducted by Celltrion for their TNF inhibitor CT-P13 SC (Infliximab). The trial aims to assess the effectiveness of CT-P13 SC in treating individuals with moderate to severe Crohn's disease. Additionally, JAK inhibitors is predicted to grow at fastest CAGR during the forecast period owing to a preference for oral administration, a quick onset of action, and growing number of product approvals for JAK inhibitors.
By route of administration, injectables was the highest revenue-grossing segment in the global inflammatory bowel disease treatment market in 2023 owing to the surge in adoption of biologics for the treatment of ulcerative colitis & Crohn's disease, growing product approvals for biologics by regulatory authorities. For instance, in May 2023, CELLTRION INC. has been granted approval by the U.S. FDA for Yuflyma (adalimumab-aaty) biosimilar, covering eight indications, which include Crohn's disease and ulcerative colitis. Additionally, oral is predicted to grow at fastest CAGR during the forecast period owing to The simplicity of self-administration in the management of mild to moderate cases of Crohn's disease & ulcerative colitis and oral drugs that are easily accessible for treating inflammatory bowel disease (IBD).
By indication, Crohn's disease was the highest revenue-grossing segment in the global inflammatory bowel disease treatment market in 2023 owing to the increasing population of patients undergoing treatment for this condition and rising occurrence of Crohn's disease. Additionally, ulcerative colitis segment is predicted to grow at fastest CAGR during the forecast period owing to the escalating number of regulatory approvals for drugs aimed at treating ulcerative colitis, and rising rate of disease treatment. For instance, in March 2022, AbbVie has disclosed that the U.S. Food and Drug Administration (FDA) has granted approval for the drug RINVOQ (upadacitinib) to be used in the treatment of adults experiencing moderate to severely active ulcerative colitis.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global inflammatory bowel disease treatment market in 2023 owing to the growing reimbursement policies and increasing approval of novel therapies by regulatory authorities. For instance, in October 2023, The U.S. Food and Drug Administration (FDA) has approved VELSIPITY (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator, according to Pfizer Inc. The purpose of this approval is to treat people with moderately to severely active ulcerative colitis (UC). Additionally, retail pharmacy & other is predicted to grow at fastest CAGR during the forecast period owing to the rising use of online pharmacies and the increasing need for drugs such as JAK inhibitors, which include easily accessible corticosteroids at retail pharmacies.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising adoption of biologics for treating ulcerative colitis and Crohn's disease, a surge in the implementation of favorable reimbursement policies for treatment, an increasing prevalence of these diseases, a growing population undergoing treatment, the availability of various treatment options for these conditions, and rising collaboration among market players. For instance, in October 2023, It has been revealed that Teva Pharmaceuticals and Sanofi are collaborating to co-develop and co-market the drug TEV’574. Phase 2b clinical studies are presently being conducted on this drug with the aim of treating inflammatory bowel diseases, specifically Crohn's disease and ulcerative colitis. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in healthcare spending, heightened awareness of ulcerative colitis and Crohn's disease, a surge in the number of individuals seeking treatment for these conditions, and a growing number of regulatory approvals for drugs designed to treat these diseases. For instance, in March 2022, In Japan, CAROGRA, has received approval for a medication given for the treatment of ulcerative colitis by EA Pharma Co., Ltd.
Growing approvals of the novel drugs for the treatment of inflammatory bowel disease by regulatory bodies is predicted to boost the market growth during the forecast period. Inflammatory bowel disease (IBD) encompasses two conditions, namely Ulcerative colitis and Crohn's disease, characterized by prolonged inflammation of the gastrointestinal (GI) tract. Persistent inflammation can lead to damage in the GI tract. Treatment for irritable bowel disease is focused on mitigating the inflammation responsible for the associated signs and symptoms. Ideally, this approach aims not only to alleviate symptoms but also to achieve long-term remission and reduce the risks of complications. For instance, in May 2023, According to a statement from AbbVie, the FDA has approved RINVOQ (upadacitinib) for the treatment of people with moderately to severely active Crohn's disease.
By drug class, TNF inhibitors was the highest revenue-grossing segment in the global inflammatory bowel disease treatment market in 2023 owing to the growing focus on development of TNF inhibitors by the key market players and surge in number of clinical trial procedures. For instance, in October 2023, Phase 3 clinical trials are presently being conducted by Celltrion for their TNF inhibitor CT-P13 SC (Infliximab). The trial aims to assess the effectiveness of CT-P13 SC in treating individuals with moderate to severe Crohn's disease. Additionally, JAK inhibitors is predicted to grow at fastest CAGR during the forecast period owing to a preference for oral administration, a quick onset of action, and growing number of product approvals for JAK inhibitors.
By route of administration, injectables was the highest revenue-grossing segment in the global inflammatory bowel disease treatment market in 2023 owing to the surge in adoption of biologics for the treatment of ulcerative colitis & Crohn's disease, growing product approvals for biologics by regulatory authorities. For instance, in May 2023, CELLTRION INC. has been granted approval by the U.S. FDA for Yuflyma (adalimumab-aaty) biosimilar, covering eight indications, which include Crohn's disease and ulcerative colitis. Additionally, oral is predicted to grow at fastest CAGR during the forecast period owing to The simplicity of self-administration in the management of mild to moderate cases of Crohn's disease & ulcerative colitis and oral drugs that are easily accessible for treating inflammatory bowel disease (IBD).
By indication, Crohn's disease was the highest revenue-grossing segment in the global inflammatory bowel disease treatment market in 2023 owing to the increasing population of patients undergoing treatment for this condition and rising occurrence of Crohn's disease. Additionally, ulcerative colitis segment is predicted to grow at fastest CAGR during the forecast period owing to the escalating number of regulatory approvals for drugs aimed at treating ulcerative colitis, and rising rate of disease treatment. For instance, in March 2022, AbbVie has disclosed that the U.S. Food and Drug Administration (FDA) has granted approval for the drug RINVOQ (upadacitinib) to be used in the treatment of adults experiencing moderate to severely active ulcerative colitis.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global inflammatory bowel disease treatment market in 2023 owing to the growing reimbursement policies and increasing approval of novel therapies by regulatory authorities. For instance, in October 2023, The U.S. Food and Drug Administration (FDA) has approved VELSIPITY (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator, according to Pfizer Inc. The purpose of this approval is to treat people with moderately to severely active ulcerative colitis (UC). Additionally, retail pharmacy & other is predicted to grow at fastest CAGR during the forecast period owing to the rising use of online pharmacies and the increasing need for drugs such as JAK inhibitors, which include easily accessible corticosteroids at retail pharmacies.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising adoption of biologics for treating ulcerative colitis and Crohn's disease, a surge in the implementation of favorable reimbursement policies for treatment, an increasing prevalence of these diseases, a growing population undergoing treatment, the availability of various treatment options for these conditions, and rising collaboration among market players. For instance, in October 2023, It has been revealed that Teva Pharmaceuticals and Sanofi are collaborating to co-develop and co-market the drug TEV’574. Phase 2b clinical studies are presently being conducted on this drug with the aim of treating inflammatory bowel diseases, specifically Crohn's disease and ulcerative colitis. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in healthcare spending, heightened awareness of ulcerative colitis and Crohn's disease, a surge in the number of individuals seeking treatment for these conditions, and a growing number of regulatory approvals for drugs designed to treat these diseases. For instance, in March 2022, In Japan, CAROGRA, has received approval for a medication given for the treatment of ulcerative colitis by EA Pharma Co., Ltd.
Segmentation: Inflammatory Bowel Disease Treatment Market Report 2023 - 2034
Inflammatory Bowel Disease Treatment Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Corticosteroids
- TNF Inhibitors
- Anti-Integrin
- ASA Drugs
- JAK Inhibitors
- IL Inhibitors
- Others
Inflammatory Bowel Disease Treatment Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Injectables
- Oral
Inflammatory Bowel Disease Treatment Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Ulcerative Colitis
- Crohn's Disease
Inflammatory Bowel Disease Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacy
- Retail Pharmacy & Others
Inflammatory Bowel Disease Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Inflammatory Bowel Disease Treatment Market: Drug Class Estimates & Trend Analysis
8. Inflammatory Bowel Disease Treatment Market: Route of Administration Estimates & Trend Analysis
9. Inflammatory Bowel Disease Treatment Market: Indication Estimates & Trend Analysis
10. Inflammatory Bowel Disease Treatment Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Inflammatory Bowel Disease Treatment Market
13. Europe Global Inflammatory Bowel Disease Treatment Market
14. Asia Pacific Global Inflammatory Bowel Disease Treatment Market
15. Latin America Global Inflammatory Bowel Disease Treatment Market
16. MEA Global Inflammatory Bowel Disease Treatment Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Biogen
- AbbVie Inc
- Lilly
- UCB S.A.
- Pfizer Inc
- Johnson & Johnson Services Inc
- CELLTRION INC.
- Novartis AG
- Merck & Co. Inc.
- Takeda Pharmaceutical Company Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 26.65 Billion |
| Forecasted Market Value ( USD | $ 49.76 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
